Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Efficacy of Favipiravir in the Treatment of Mild to Moderate COVID-19 Patients in Erbil: A Controlled Clinical Trial

Qadir et al., International Journal of Applied Sciences: Current and Future Research Trends, 13:1
May 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Mortality 97% Improvement Relative Risk Hospitalization 60% Recovery, day 30 97% primary Recovery, day 15 71% Recovery, day 10 79% Recovery, day 5 71% Recovery time 58% Favipiravir  Qadir et al.  EARLY TREATMENT Is early treatment with favipiravir beneficial for COVID-19? Prospective study of 250 patients in Iraq (June 2020 - October 2021) Lower mortality (p<0.0001) and hospitalization (p=0.0013) c19early.org Qadir et al., Int. J. Applied Sciences.., May 2022 Favors favipiravir Favors control
Prospective study with 125 favipiravir patients and 125 patients declining favipiravir treatment, showing lower mortality and improved recovery with treatment. All patients received vitamin C, D, and zinc. Favipiravir 3200mg day 1, followed by 600mg bid days 2-10.
risk of death, 97.1% lower, RR 0.03, p < 0.001, treatment 0 of 125 (0.0%), control 17 of 125 (13.6%), NNT 7.4, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 30.
risk of hospitalization, 60.0% lower, RR 0.40, p = 0.001, treatment 14 of 125 (11.2%), control 35 of 125 (28.0%), NNT 6.0.
risk of no recovery, 97.1% lower, RR 0.03, p < 0.001, treatment 0 of 125 (0.0%), control 17 of 125 (13.6%), NNT 7.4, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 30, primary outcome.
risk of no recovery, 70.8% lower, RR 0.29, p < 0.001, treatment 14 of 125 (11.2%), control 48 of 125 (38.4%), NNT 3.7, day 15.
risk of no recovery, 78.8% lower, RR 0.21, p < 0.001, treatment 14 of 125 (11.2%), control 66 of 125 (52.8%), NNT 2.4, day 10.
risk of no recovery, 70.6% lower, RR 0.29, p < 0.001, treatment 32 of 125 (25.6%), control 109 of 125 (87.2%), NNT 1.6, day 5.
recovery time, 58.1% lower, relative time 0.42, p < 0.001, treatment 125, control 125.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Qadir et al., 23 May 2022, prospective, Iraq, peer-reviewed, 3 authors, study period 22 June, 2020 - 25 October, 2021.
This PaperFavipiravirAll
International Journal of Applied Sciences: Current and Future Research Trends
Hiwa Khalid Qadir, Hama Nejm Jaff, Hemin Khalid Saber
Background and objectives: Favipiravir (FAV) is considered to have potential efficacy against the SARS-CoV-2 virus. We aimed to explore the efficacy of favipiravir in the treatment of mild and moderate cases of COVID-19 pneumonia. Methods: 250 patients of mild and moderate COVID-19 patients confirmed by reverse transcription-polymerase chain reaction (RT-PCR) were included from 22 nd of June 2020 till 25 th of October 2021, aged 18 to 90 years, 125 patients received FAV 3200 mg no day 1 followed by 600 mg twice daily (from day 2 -day 10). In another group, 125 patients did not receive favipiravir (SOC, standard of care group). They received paracetamol, vitamins D, and C plus Zinc, and azithromycin within the first 10 days of symptoms' onset. In both groups, the patients were monitored for clinical recovery on the 5 th ,10 th, 15 th days and after one month of receiving the therapeutic trials. Patients were enrolled from Rizgari Teaching Hospital, and from an outpatient respiratory private clinic. Both arms were comparable as regards demographic characteristics, severity, and comorbidities. It was a non-randomized -controlled trial. Results: On day five, the rate of clinical improvement in the FAV group (74.4%) was significantly (p < 0.001) higher than the rate in the SOC group (12.8%). On day 10, the mentioned rate was 88.8% in the FAV group compared with 47.2% in the SOC group (p < 0.001). The median time of clinical recovery was 6.5 days in the FAV group vs.
References
Abdulah, Qazli, Suleman, Response of the Public to Preventive Measures of COVID-19 in Iraqi Kurdistan, Disaster Med Public Health Prep, doi:10.1017/dmp.2020.233
Bhagat, Vora, Daxini, Dadhich, Patil et al., Clinical usefulness of favipiravir in moderate COVID-19 patients: Indian real-world experience, Indian Journal of Critical Care Medicine
Cai, Yang, Liu, Chen, Shu et al., treatment with favipiravir for COVID-19: an open-label control study, Experimental International Journal of Applied Sciences: Current and Future Research Trends (IJASCFRT)
Dabbous, El-Sayed, Assal, Elghazaly, Ebeid et al., Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial, Scientific reports
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proceedings of the Japan Academy, Series B
Hayden, Shindo, Influenza virus polymerase inhibitors in clinical development. Current opinion in infectious diseases
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The lancet
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial, medRxiv
Liu, Chang, Wang, Tsai, Hung et al., Prolonged virus shedding even after seroconversion in a patient with COVID-19, J Infect
Madelain, Oestereich, Graw, Nguyen, De Lamballerie et al., Ebola virus dynamics in mice treated with favipiravir, Antiviral research
Ruzhentsova, Oseshnyuk, Soluyanova, Dmitrikova, Mustafaev et al., Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19, American Journal of Translational Research
Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, International Journal of Infectious Diseases
Zhonghua, He, Hu, Za, Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia, Bibl. Nac. Med
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit